IFM Investors Pty Ltd Has $171.13 Million Stake in Eli Lilly and Company $LLY

IFM Investors Pty Ltd lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 1.1% in the 4th quarter, HoldingsChannel reports. The fund owned 159,239 shares of the company’s stock after purchasing an additional 1,667 shares during the period. Eli Lilly and Company makes up approximately 1.4% of IFM Investors Pty Ltd’s investment portfolio, making the stock its 10th biggest holding. IFM Investors Pty Ltd’s holdings in Eli Lilly and Company were worth $171,131,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in LLY. Brighton Jones LLC increased its position in shares of Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after acquiring an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC boosted its holdings in Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after purchasing an additional 40 shares during the last quarter. Schnieders Capital Management LLC. grew its position in Eli Lilly and Company by 16.7% in the 2nd quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock worth $6,231,000 after purchasing an additional 1,141 shares in the last quarter. Flow Traders U.S. LLC bought a new stake in Eli Lilly and Company in the 2nd quarter worth about $356,000. Finally, Nebula Research & Development LLC bought a new stake in Eli Lilly and Company in the 2nd quarter worth about $749,000. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Up 2.2%

LLY opened at $1,161.75 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The stock has a market cap of $1.09 trillion, a price-to-earnings ratio of 41.27, a PEG ratio of 1.24 and a beta of 0.53. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,182.73. The company’s 50-day moving average price is $994.84 and its two-hundred day moving average price is $1,015.87.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The firm had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The company’s quarterly revenue was up 55.5% on a year-over-year basis. During the same period in the previous year, the company earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities analysts expect that Eli Lilly and Company will post 35.8 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th were paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date was Friday, May 15th. Eli Lilly and Company’s payout ratio is presently 24.58%.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of recent analyst reports. Wall Street Zen raised shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 2nd. Barclays upped their price objective on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an “overweight” rating in a research report on Monday, May 4th. UBS Group reaffirmed a “buy” rating on shares of Eli Lilly and Company in a research report on Wednesday, March 18th. HSBC downgraded shares of Eli Lilly and Company from a “hold” rating to a “reduce” rating and reduced their price objective for the stock from $1,070.00 to $850.00 in a research report on Tuesday, March 17th. Finally, Berenberg Bank upped their price objective on shares of Eli Lilly and Company from $950.00 to $1,050.00 and gave the stock a “hold” rating in a research report on Thursday, February 19th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,227.74.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Recent reporting says Eli Lilly remains ahead of rivals in the booming obesity-drug market, reinforcing confidence in the company’s dominant position and growth outlook. Focus: Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon
• Positive Sentiment: FDA approval for expanded EBGLYSS maintenance dosing to once every eight weeks gives Lilly another commercial win outside obesity and diabetes, while improving convenience for patients and broadening the drug’s appeal. FDA approves Lilly’s EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis
• Positive Sentiment: Lilly also expanded its chronic pain pipeline with new Phase 2 trials in osteoarthritis and chronic low back pain, suggesting more long-term growth opportunities beyond its current blockbuster drugs. Eli Lilly Expands Chronic Pain Pipeline With New Osteoarthritis Trial
• Positive Sentiment: Analysts remain constructive, with Erste Group nudging up FY2026 EPS estimates and Jefferies raising its price target to $1,350 while keeping a Buy rating, both of which can help investor sentiment. Is Eli Lilly and Company (LLY) One of the 10 Best Dividend Stocks to Buy According to D. E. Shaw?
• Neutral Sentiment: Broader healthcare-sector strength is providing a supportive backdrop for LLY, but this is more of an industry tailwind than a company-specific catalyst. Sector Update: Healthcare Stocks Higher Late Afternoon
• Neutral Sentiment: Media attention around GLP-1 coverage cuts by some employers could create some headwinds over time, but it also underscores how central Lilly’s obesity franchise has become to the healthcare cost debate. Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.